M7824
Feb 07, 2019
Genentech remunerates Xencor; XPrize upraises fund; GSK gambles
Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
